Back to Test Catalogue

Quinidine, Serum

Test ID: QUIN

Test

Method

Kinetic Interaction of Microparticles in Solution (KIMS) Immunoassay

Method Description

The assay is a homogeneous immunoassay based on the principle of measuring changes in scattered light or absorbance, which result when activated microparticles aggregate. The microparticles are coated with quinidine and rapidlyaggregate in the presence of a quinidine antibody solution. When a sample containing quinidine is introduced, the aggregation reaction is partially inhibited, slowing the rate of the aggregation process. Antibody bound to sample drug is no longer available to promote microparticle aggregation, and subsequent particle lattice formation is inhibited. Thus, a classic inhibition curve with respect to quinidine concentration is obtained, with the maximum rate of aggregation at the lowest quinidine concentration. By monitoring the change in scattered light or absorbance, a concentration-dependent curve is obtained.(Package insert: Roche Quinidine reagent, Roche Diagnostic Corp, Indianapolis, IN)

Report Includes

Quinidine (µg/mL); Quinidine (µmol/L)

Specimens

Avoid gel separator tubes; Serum

Test Location

Mayo Clinical Labs, Minnesota USA

Test Version

30-Sep-2019

Specimen

Specimens

Avoid gel separator tubes; Serum

Sample Volume

0.25 mL

Specimen Comment

Avoid gel separator tubes.

Collection & Handling

Handling Information

Separate within 2 hours. Store and send cold or frozen.

Stability

Ambient 14 days
Refrigerated 14 days
Frozen 14 days

Test Version

30-Sep-2019

Performance / Interpretation

Method

Kinetic Interaction of Microparticles in Solution (KIMS) Immunoassay

Method Description

The assay is a homogeneous immunoassay based on the principle of measuring changes in scattered light or absorbance, which result when activated microparticles aggregate. The microparticles are coated with quinidine and rapidlyaggregate in the presence of a quinidine antibody solution. When a sample containing quinidine is introduced, the aggregation reaction is partially inhibited, slowing the rate of the aggregation process. Antibody bound to sample drug is no longer available to promote microparticle aggregation, and subsequent particle lattice formation is inhibited. Thus, a classic inhibition curve with respect to quinidine concentration is obtained, with the maximum rate of aggregation at the lowest quinidine concentration. By monitoring the change in scattered light or absorbance, a concentration-dependent curve is obtained.(Package insert: Roche Quinidine reagent, Roche Diagnostic Corp, Indianapolis, IN)

Turnaround Time

7 days

Specimen Retention Time

7 days

Results

Name Units Reference Range Conversion Factor
Quinidine µg/mL
  • Therapeutic 2.0 - 5.0
  • Toxic: ≥6.0
µmol/L x 0.325
Quinidine µmol/L
  • Therapeutic 6.2 - 15.4
  • Toxic: ≥18.5
µg/mL x 3.08

Test Location

Mayo Clinical Labs, Minnesota USA

Test Version

30-Sep-2019

Interface / Setup

Test Version

30-Sep-2019